

Southern Illinois University Edwardsville

**SPARK**

---

SIUE Faculty Research, Scholarship, and Creative Activity

---

Summer 7-21-2015

## Quantitative Sequencing for the Determination of Kdr-type Resistance Allele (V419L,L925I, I936F) Frequencies in Common Bed Bug, *Cimex lectularius* L., (Hemiptera: Cimicidae) Populations Collected from Israel

Daniel J. Palencar

*University of Massachusetts - Amherst*

Kyle J. Gellatly

*University of Massachusetts - Amherst*

Kyong-Sup Yoon

*Southern Illinois University Edwardsville, kyoony@siue.edu*

Kosta Y. Mumcuoglu

*Hebrew University-Jerusalem*

Uri Shalom

*Ministry of Environmental Protection, Jerusalem, Israel*

Follow this and additional works at: [https://spark.siu.edu/siue\\_fac](https://spark.siu.edu/siue_fac)



Participate for additional authors, Environmental Health Commons, and the Toxicology Commons

---

### Recommended Citation

Palencar, Daniel J.; Gellatly, Kyle J.; Yoon, Kyong-Sup; Mumcuoglu, Kosta Y.; Shalom, Uri; and Clark, J Marshall, "Quantitative Sequencing for the Determination of Kdr-type Resistance Allele (V419L,L925I, I936F) Frequencies in Common Bed Bug, *Cimex lectularius* L., (Hemiptera: Cimicidae) Populations Collected from Israel" (2015). *SIUE Faculty Research, Scholarship, and Creative Activity*. 12. [https://spark.siu.edu/siue\\_fac/12](https://spark.siu.edu/siue_fac/12)

This Article is brought to you for free and open access by SPARK. It has been accepted for inclusion in SIUE Faculty Research, Scholarship, and Creative Activity by an authorized administrator of SPARK. For more information, please contact [jkohlbu@siue.edu](mailto:jkohlbu@siue.edu).

---

**Authors**

Daniel J. Palencar, Kyle J. Gellatly, Kyong-Sup Yoon, Kosta Y. Mumcuoglu, Uri Shalom, and J Marshall Clark

**Quantitative Sequencing for the Determination of Kdr-type Resistance Allele (V419L, L925I, I936F) Frequencies in Common Bed Bug, *Cimex lectularius* L., (Hemiptera: Cimicidae) Populations Collected from Israel**

Journal:	<i>Journal of Medical Entomology</i>
Manuscript ID:	JME-2015-0010.R1
Manuscript Type:	Research Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Clark, John; University of Massachusetts Amherst, Veterinary and Animal Science Palenchar, Daniel; University of Massachusetts, Amherst, Molecular Biology & Biochemistry Gellatly, Kyle; University of Massachusetts, Amherst, Molecular and Cellular Biology Sup Yoon, Kyong; Southern Illinois University, Biological Sciences and Environmental Sciences Program Mumcuoglu, Kosta Y.; Hebrew University-Hadassah Medical School, Parasitology Unit, Dept. of Microbiology Shalom, Uri; Ministry of the Environment, Division of Pest Surveillance and Control
<b>Please choose a section from the list</b>:	Vector Control, Pest Management, Resistance, Repellents
Field Keywords:	Resistance, Resistance Management
Organism Keywords:	Cimex

SCHOLARONE™  
 Manuscripts

1 **For publication in:**  
2 Journal of Medical Entomology  
3 JME-2015-0010 revision 1  
4 6-16-2015

Send comments and proofs to:  
Dr. J. Marshall Clark<sup>a</sup>  
Dept. of Veterinary & An. Sci.  
N311B Morrill 1  
637 North Pleasant St.  
University of Massachusetts  
Amherst, MA 01003  
Tel: (413) 545-1052  
Fax: (413) 577-4267  
E-mail: jclark@vasci.umass.edu

12 **Quantitative Sequencing for the Determination of Kdr-type Resistance Allele (V419L,**  
13 **L925I, I936F) Frequencies in Common Bed Bug, *Cimex lectularius* L., (Hemiptera:**  
14 **Cimicidae) Populations Collected from Israel**

16 Daniel J. Palenchar<sup>1</sup>, Kyle J. Gellatly<sup>2</sup>, Kyong Sup Yoon<sup>3</sup>, Kosta Y. Mumcuoglu<sup>4</sup>, Uri Shalom<sup>5</sup>,  
17 J. Marshall Clark<sup>2,6,a</sup>

19 <sup>1</sup>Department of Molecular Biology & Biochemistry, University of Massachusetts, Amherst, MA

20 <sup>2</sup>Molecular and Cellular Biology Program, University of Massachusetts, Amherst, MA

21 <sup>3</sup>Department of Biological Sciences and Environmental Sciences Program, Southern Illinois  
22 University, Edwardsville, IL 62026

23 <sup>4</sup>Parasitology Unit, Department of Microbiology and Molecular Genetics, the Kuvim Center for  
24 the Study of Infectious and Tropical Diseases, the Hebrew University-Hadassah Medical  
25 School, Jerusalem, Israel

26 <sup>5</sup>Division of Pest Surveillance and Control, Ministry of Environmental Protection, Jerusalem,  
27 Israel

28 <sup>6</sup>Department of Veterinary and Animal Sciences, University of Massachusetts, Amherst, MA

30 **Running head:** Palenchar et al: Knockdown Resistance in Bed Bugs from Israel

31 Number of Figures: 4

32 Number of Tables: 4

33

34 **ABSTRACT**

35 Human bed bug infestations have dramatically increased worldwide since the mid-1990s. A  
36 similar phenomenon was also observed in Israel since 2005, when infestations were reported  
37 from all over the country. Two single nucleotide polymorphisms (V419L and L925I) in the bed  
38 bug voltage sensitive sodium channel confer *kdr*-type resistance to pyrethroids. Using  
39 quantitative sequencing (QS), the resistance allele frequencies of Israeli bed bug populations  
40 from across the country were determined. Genomic DNA was extracted from samples of 12  
41 populations of bed bugs collected from Israel and DNA fragments containing the V419L or  
42 L925I and I936F mutations sites were PCR amplified. The PCR products were analyzed by QS  
43 and the nucleotide signal ratios calculated and used to predict the resistance allele frequencies of  
44 the unknown populations. Results of the genetic analysis show that resistant nucleotide signals  
45 are highly correlated to resistance allele frequencies for both mutations. Ten of the 12 tested  
46 populations had 100% of the L925I mutation and 0% of the V419L mutation. One population  
47 was heterogeneous for the L925I mutation and had 0% of the V419L mutation and another  
48 population was heterozygous for the V419L mutation and had 100% of the L925I mutation.  
49 I936F occurred only at low levels. These results indicate that bed bugs in Israel are genetically  
50 resistant to pyrethroids. Thus, pyrethroids should only be used for bed bug management with  
51 caution using effective application and careful monitoring procedures. Additionally, new and  
52 novel-acting insecticides and non-chemical means of controlling bed bugs should be explored.

53

54

55

56 **Key Words:** *Cimex lectularius*, common bed bug, Israel, knockdown resistance (*kdr*),  
57 pyrethroids, quantitative sequencing.

58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74

## 75 INTRODUCTION

76 *Cimex lectularius* L., the common bed bug, is an obligatorily hematophagous  
77 ectoparasitic insect that feeds on a variety of warm blooded mammals including humans  
78 (Usinger 1966, Boase 2004, Thomas et al. 2004, Reinhardt and Siva-Jothy 2007, Tawatsin et al.  
79 2011, Zhu et al. 2010). *C. lectularius* is widely distributed throughout temperate parts of the  
80 globe, and poses serious economic, psychological, and physiological problems to humans.  
81 Effective monitoring and managing of bed bug populations and preventing or delaying  
82 development of insecticide resistance are keys to reducing and eliminating the ramifications that  
83 accompany their presence.

84 Human reactions to *C. lectularius* bites are highly variable (Boase 2004, Thomas et al.  
85 2004, Wang et al. 2011). The initial bite of a bug is usually not felt. However, later the bite site  
86 itches, swells, burns, becomes inflamed or forms a weal and is very disturbing for the victim.  
87 There may be a central punctum at the site of the bite. Recurrent bites are often concentrated on  
88 the arms, legs and back, as well as on the face around the eyes. Lesions are frequently present in  
89 linear or clustered arrangements (Mumcuoglu, 2008). It is generally believed that bed bugs are  
90 not likely a vector for human disease (Blow et al. 2001, Boase 2004, Moore and Miller 2006,  
91 Reinhardt and Siva-Jothy 2007, Romero et al. 2007, Weeks et al. 2011, Doggett et al. 2012).  
92 Recently, Salazar et al. (2014) have shown that the common bed bug may be vector of  
93 *Trypanosoma cruzi* and could pose a risk for vector-borne transmission of Chagas disease.  
94 However, there is no evidence that the common bed bud actually transmits this pathogen in the  
95 field.

96 *C. lectularius* was a well-known parasite in human dwellings throughout the world until  
97 the end of WWII. The prevalence of common bed bug infestations decreased dramatically in

98 developed countries until the 1980s, largely due to the introduction and widespread use of  
99 insecticides, such as DDT and malathion, and probably the improvement in housing conditions  
100 and hygiene (Usinger 1966, Reinhardt and Siva-Jothy 2007). Bed bug infestations increased  
101 dramatically after the mid-1990s in the United States, the United Kingdom, various other  
102 European countries (Koganemaru and Miller 2013), Australia, Brazil, Chile (Faundez and  
103 Carvajal 2014) and China (Wang et al. 2013).

104 Infestations by the common bed bug were very common in what today is Israel until  
105 WWII (Kaufmann 1938, Dolev 2007). With the intensive use of DDT and lindane, the parasite  
106 became very rare and the few remaining pests were most probably those that became resistant to  
107 DDT (Levinson 1953, Cwilich et al. 1957, Gratz 1958, 1959, Busvine 1977, Mumcuoglu, 2008).  
108 During the years of 2006-2008, a 50-150% increase in the reported cases of infestations occurred  
109 in comparison to the period of 2001-2005. Bed bugs were mainly reported in hotels, residences  
110 and prisons, as well as in industrial buildings (Mumcuoglu and Shalom 2010). The most  
111 commonly used insecticides during this time were pyrethroids, followed by organophosphorous  
112 and carbamate insecticides. Banning the use of organophosphates inside houses and work places,  
113 as well as increasing numbers of foreign workers and new immigrants from developing  
114 countries, were considered additional factors for the increased number of bed bug infestations.

115 Bed bugs have proven to be very difficult pests to control, and insecticides have been  
116 used widely to control existing infestations (Thomas et al. 2004) and prevent reinfestations  
117 (Weeks et al. 2011). The selection of insecticide-resistant bed bugs is a significant contributing  
118 factor to their recent resurgence. Various strains of bed bugs from different geographical  
119 locations can have different resistance mechanisms (Yoon et al. 2008, Kilpinen et al. 2008, Zhu  
120 et al. 2013, Romero et al. 2009, Bai et al. 2011).



121 Bed bugs have demonstrated strong resistance to the pyrethroids (Seong et al. 2010), a  
122 class of insecticide that has been favored for bed bug control due to their high efficacy and low  
123 mammalian toxicity (Yoon et al. 2008). To date, bed bugs have developed multiple resistance  
124 mechanisms against pyrethroids, such as target site insensitivity due to mutations in the alpha-  
125 subunit of the voltage-sensitive sodium channel (VSSC), increased xenobiotic metabolism, and  
126 decreased cuticular penetration (Yoon et al. 2008, Zhu et al. 2013, Adelman et al. 2011,  
127 Mamidala et al. 2011, Koganemaru et al. 2013, Dang et al., 2013).

128 Pyrethroids target neuronal VSSCs of insects, which functions to generate and propagate  
129 action potentials in neurons (Zhu et al. 2010, Castèle and Catterall 2000). Pyrethroids selectively  
130 modify VSSC causing “repetitive discharge in motor and sensory axons and convulsive activity”,  
131 which leads to paralysis and death (Morin et al. 2002). Widespread use of DDT following World  
132 War II may have inadvertently selected bed bugs for pyrethrins/pyrethroid resistance as DDT  
133 and pyrethrins/pyrethroids share the same target site (Busvine 1958, Zhu et al. 2010, Moore and  
134 Miller 2006, Boase 2004, Yoon et al. 2008). Point mutations in the alpha subunit of the VSSC in  
135 insects confer resistance to pyrethroids through target site insensitivity, resulting in knockdown  
136 resistance (*kdr*) (Yoon et al. 2008). *Kdr* and *kdr*-type mutations have been identified in many  
137 insects and result in DDT resistance and cross-resistance to the pyrethrins/pyrethroids (Clark et  
138 al. 2013).

139 Two mutations, a valine to leucine (V419L) and a leucine to isoleucine (L925I), have  
140 been identified by Yoon et al. (2008) in the highly deltamethrin-resistant common bed bug  
141 population (NY-BB), which conferred *kdr*-type resistance to pyrethroids. Both of these  
142 mutations result from single nucleotide polymorphisms (SNPs: **GTC**→**CTC** and **CTT**→**ATT** for  
143 V419L and L925I, respectively) in the alpha subunit gene of the common bed bug VSSC

144 (*Chvssc*). A novel mutation I936F has also been identified in a single *d*-allethrin-resistant  
145 common bed bug population from Adelaide, Australia, but it appears to give only low levels of  
146 resistance and has not been validated as a *kdr*-type mutation functionally (Dang et al. 2014).

147 Using this information, a quantitative sequencing (QS) protocol was developed to  
148 establish a population-based genotyping method as a molecular monitoring tool to predict the *kdr*  
149 allele frequencies in common bed bug populations (Seong et al. 2010). The *kdr* allele frequencies  
150 in different bed bug populations calculated by QS correlated well with filter contact vial bioassay  
151 data, confirming the role of the two mutations in pyrethroid resistance (Seong et al. 2010).  
152 Similar approaches based on these initial findings have been used widely to establish the role of  
153 these two mutation in pyrethroid resistance in many common bed bug populations worldwide  
154 (Zhu et al. 2010, Tawatsin et al. 2011, Durand et al. 2012, Tawatsin et al. 2013, Dang et al.  
155 2014).

156 The purpose of this study was to predict the resistance allele frequencies of *kdr*-type  
157 mutations in common bed bug populations collected from 12 locations across Israel. This  
158 information is critical for those attempting to manage bed bug infestations in Israel, including  
159 homeowners and pest management professionals, at a time when current approaches are failing  
160 and infestations are increasing. Prior testing in other countries has shown that the frequencies of  
161 *kdr*-type alleles are highly correlated to pyrethroid resistance (Yoon et al. 2008, Seong et al.  
162 2010). Therefore, we hypothesize that the same two *kdr*-like mutations found in pyrethroid-  
163 resistant bed bugs elsewhere (V419L and L925I) will also be found at high frequencies in the  
164 Israeli populations. Additionally, previous information has identified that the L925I mutation is  
165 particularly important in conferring neuronal insensitivity and pyrethroid resistance in bed bugs

166 (Yoon et al. 2008, Seong et al. 2010, Zhu et al. 2010). This study aims to contribute additional  
167 information towards validating or rejecting that hypothesis.

168

## 169 **MATERIALS AND METHODS**

### 170 **Collection of common bed bug samples**

171 Bed bugs were collected by pest management professionals in Israel prior to treating the  
172 infested area with insecticide. The 12 collection sites were five apartments, three one-family  
173 houses, two hotels and two industrial buildings. Each population came from a different location  
174 in Israel (Table 1). Bed bugs (8-12 per location) were individually removed from their normal  
175 habitats, including but not limited to beds, wall carpets and frames and stored in 70% ethanol  
176 prior to processing. Bed bugs were collected between February 2011 and April 2012 and sent to  
177 the Pesticide Toxicology Laboratory, University of Massachusetts-Amherst, for genotyping  
178 analysis by QS.

179

180

### 181 **Sample selection for DNA extraction**

182 All stored bed bugs from a common collection site/population were washed by removing  
183 the 70% ethanol and placing them into a 1.5 mL tube with 1 ml DNase free, double-distilled,  
184 H<sub>2</sub>O (ddH<sub>2</sub>O) and gently mixing the tubes by hand shaking. After 1-2 min, the wash solution was  
185 removed using a pipette. For each population, a single test sample, labeled BBM1 to BBM12,  
186 was prepared by first separating the different developmental stages. Life stages were determined  
187 by visual inspection according to Boase (2004) and Thomas et al. (2004). A single life stage (the  
188 largest and most abundant in the population) was selected as the test sample while all other bed

189 bugs were recombined and stored in 95% ethanol at -20°C. All test samples had multiple bed  
190 bugs of the same life stage (Table 2).

### 191 **Genomic DNA extraction**

192 Genomic DNA (gDNA) was extracted from the 12 test samples (BBM1-12) using the  
193 DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA) following the manufacturer's instructions.  
194 Briefly, all bed bugs in a test sample were placed into 2 mL micro-centrifuge tubes containing  
195 180  $\mu\text{L}$  Buffer ATL, 0.9  $\mu\text{L}$  reagent DX and five stainless steel grinding balls (0.25 g, SPEX  
196 Sample Prep, Metuchen, NJ) and homogenized in an automated homogenizer (Geno Grinder  
197 2010, SPEX Sample Prep, Metuchen, NJ) at 1250 strokes per min for 1 min. Proteinase K (20  
198  $\mu\text{L}$ ) was added to the tube and incubated for 3-24 h at 56°C. Following incubation, the lysate was  
199 transferred to a 1.5 mL tube with 100% ethanol (200  $\mu\text{L}$ ) and Buffer AL (200  $\mu\text{L}$ ) and vortexed.  
200 The sample was transferred to a DNeasy Mini spin column (Qiagen), and centrifuged for 30 s at  
201 6000g. The flow through was discarded and the column placed into a new collection tube before  
202 washing with 500  $\mu\text{L}$  buffer AW1, followed by 500  $\mu\text{L}$  buffer AW2 with centrifuging for 30 s at  
203 20,000g at each wash. The column was dried by centrifugation for 3 min at 20,000g before DNA  
204 elution. The column was placed into a new collection tube and incubated for 1 min with 50  $\mu\text{L}$   
205 buffer AE and centrifuged for 1 min at 6,000g to elute the DNA. This step was repeated to  
206 maximize total DNA yield.

### 207 **Quantification of gDNA**

208 1  $\mu\text{L}$  of extracted gDNA from a single test sample was applied to a NanoDrop ND 8000  
209 UV-Vis spectrophotometer (NanoDrop Technologies, Wilmington, DE), absorbance at 260 nm  
210 determined and used to calculate the DNA concentration in ng of DNA  $\mu\text{L}^{-1}$  using a modified  
211 Beer-Lambert equation. DNA purity was also determined by the ratio between absorbencies at

212 260 and 280 nm, with ratios between 1.5 and 1.8 indicative of pure samples. Samples were  
213 diluted to a concentration of 10 ng/ $\mu$ L and stored at -20°C.

#### 214 **PCR amplification of gDNA**

215 15  $\mu$ L of a master mix (12  $\mu$ L ddH<sub>2</sub>O, 5  $\mu$ L 5X Advantage HD Buffer, 1.75  $\mu$ L 2.857  
216 mM dNTP mixture, 0.25  $\mu$ L Advantage HD Polymerase and 1  $\mu$ L of a 10 mM solution  
217 containing the forward and reverse primers for either V419L or L925I and I936F, Table 3) were  
218 mixed with 5  $\mu$ L of template DNA (10 ng/ $\mu$ L) and placed onto an Eppendorf Mastercycler Pro  
219 (Hamburg, Germany) thermal cycler operated using the following parameters: 1 cycle at 95.0°C  
220 for 1 min; by 35 cycles of: 30 s at 95.0°C, 30 s at 61.0°C; and 1 min at 72.0°C. Gel  
221 electrophoresis (0.9% agarose) was used to verify quality and quantity of PCR DNA fragment  
222 amplification using ethidium bromide (1  $\mu$ L of 10 mg/mL stock) staining to visualize PCR  
223 products under UV light. Where present, positive controls used an individual bed bug sample  
224 (BBS5) obtained from a laboratory-reared bed bug colony (FL-BB, Yoon et al, 2008). Negative  
225 controls for the PCR reaction used ddH<sub>2</sub>O as template, and in all cases no band was present after  
226 PCR amplification. This confirms that all reagents were free from gDNA contamination.

#### 227 **PCR product purification:**

228 The QIAquick PCR Purification Kit (Qiagen) was used for PCR product purification  
229 following the manufacturer's instructions. Briefly, 5 volumes of buffer PB were added to 1  
230 volume PCR product, mixed with 10  $\mu$ L of 3M sodium acetate buffer, transferred to a QIAquick  
231 spin column placed in a 2 mL collection tube and centrifuged for 30 s at 20,000g. The column  
232 was first washed with 750  $\mu$ L guanidine HCl (30 s) and then with 750  $\mu$ L buffer PE (30 s). After  
233 drying by centrifugation, DNA was eluted into a 1.5 mL tube by applying 50  $\mu$ L and then 30  $\mu$ L

234 of Buffer EB and centrifuging at 20,000g for 1 min. Gel electrophoresis (0.9% agarose) was used  
235 to verify quantity and quality of products as above.

### 236 **Standard curve for QS analysis**

237 The QS protocol developed by Seong et al. (2010) was followed and standard curves  
238 generated using the deltamethrin-resistant NYS-BB (Seong et al. 2010) and the insecticide-  
239 susceptible FL-BB (Yoon et al. 2008) strains of bed bugs for both mutations. Resistant and  
240 susceptible nucleotide signal intensities for each mixture were determined from sequence  
241 chromatograms and used to calculate nucleotide signal ratios (NSR) ( $[\text{resistant nucleotide signal}]$   
242  $/ [\text{resistant nucleotide signal} + \text{susceptible nucleotide signal}]$ ). Resulting nucleotide signal ratios  
243 were plotted against known resistant allele frequencies to generate standard curve equations as  
244 well as lower and upper prediction band equations (Fig. 1) using Sigma Plot 10.0 (Systat  
245 Software Inc., San Jose, CA). The standard curves were used to predict resistance allele  
246 frequencies for the 12 unknown Israeli BBM populations at the 95% confidence level (Seong et  
247 al. 2010). A standard curve for the I936F mutation was not generated as the NSR values were  
248 consistently low.

249

### 250 **Determination of unknown resistant allele frequencies**

251 Triplicates for each test sample (BBM1-12), containing 5  $\mu\text{L}$  of a 5  $\mu\text{M}$  sequencing  
252 primer solution (3VLQS for V419L and 5LIQS for L925I and I936F, Table 3), were mixed with  
253 10  $\mu\text{L}$  of purified PCR product (Fig. 2) at a concentration of (1  $\text{ng}/\mu\text{L}$ ), loaded into a 96 well  
254 plate and sent to GeneWiz (South Plainfield, NJ) for sequencing. Sequence chromatograms were  
255 analyzed using Chromas lite software (Technelysium Pty Ltd., Tewantin, Australia) to determine

256 the nucleotide signal intensity at the respective mutation site (Fig. 3). NSR were calculated and  
257 used to predict resistance allele frequency from the Standard curves (Seong et al. 2010).

258

## 259 RESULTS

260 Standard curves for the V419L and L925I mutations were generated from known  
261 populations of deltamethrin-resistant and susceptible bed bugs (Fig. 1). The equation for the  
262 V419L and L925I standard curves were:  $Y = 3.6754(1-[0.7271]^x)$  and  $Y = 2.0146(1-[0.4914]^x)$ ,  
263 respectively, where Y is the resistance allele frequency. The curves show that the resistant and  
264 susceptible nucleotide signal intensities, which were used to determine the NRSs, were highly  
265 correlated to resistance allele frequencies with an  $R^2$  value of 0.998 and 0.996 for the V419L and  
266 L925I curves, respectively. The V419L curve had smaller 95% prediction bands than the L925I  
267 curve, which may be due to different efficiencies in the dideoxy nucleotide terminator  
268 incorporation between the resistant and susceptible nucleotides in the sequencing reaction  
269 (Korch and Drabkin 1999).

270 After extracting gDNA from the 12 Israeli bed bug populations, absorbencies of the  
271 eluents were determined spectrophotometrically to determine the concentration and purity. For  
272 each test sample, the DNA concentrations (ng/ $\mu$ L) and purity (A260/A280 values) were as  
273 follows: BBM1 (123, 1.8), BBM2 (53, 1.7), BBM3 (43, 1.9), BBM4 (13, 2.9), BBM5 (76, 2.1),  
274 BBM6 (41, 1.9), BBM7 (94, 2.0), BBM8 (72, 1.9), BBM9 (120, 1.9), BBM10 (78, 2.1), BBM11  
275 (120, 2.2), BBM12 (5.5, 2.2) All test samples yielded sufficient DNA (~10 ng/ $\mu$ L) of required  
276 purity for PCR amplification.

277 Two separate PCR reactions were performed on the 12 test sample eluents (BBM1-12) to  
278 amplify DNA fragments encompassing the V419L or L925I and I936F mutation sites within the

279 alpha subunit gene of *Clvssc*. The size and quality of the PCR products were determined by  
280 electrophoresis on a 0.9% agarose gel with ethidium bromide staining. The expected sizes of the  
281 V419L or L925I and I936F PCR products were 354 and 360 base pairs (bp), respectively.

282 The PCR products were purified and subjected to electrophoresis (Fig. 2). Bands at the  
283 expected sizes for the V419L or the L925I and I936F mutations confirmed the presence of the  
284 alleles of interest, and a band was present in the positive control, while no band was present in  
285 the negative control. Purified PCR products were sent to GeneWiz for sequencing. These  
286 sequences were analyzed with the QS protocol to determine the presence or absence of the three  
287 point mutations in the 12 test samples.

288 The resistance allele frequencies at the V419L mutation for all populations were 0.0 with  
289 the exception of BBM9, which was heterogeneous with a resistance allele frequency of 0.39  
290 (Table 4). The resistance allele frequency of 0.0 corresponds to a 0% incidence of the V419L  
291 resistant allele in 11 of the 12 test samples. The 0.39 resistance allele frequency associated with  
292 one of the 12 populations samples (BBM9) corresponds to a 39% presence of the resistant allele  
293 at this site.

294 The resistance allele frequency for the L925I mutation was 1.0 (100% presence of the  
295 L925I-resistant allele, all bed bugs within a sample have the mutation) for 11 of the 12  
296 populations tested (Table 4). The exception was the BBM10 sample, which had a resistance  
297 allele frequency of 0.61 (61%), indicating that this population was heterogeneous for the L925I  
298 mutation. NSRs were likewise determined for the I936F mutation for all samples but only ranged  
299 from 0.06 to 0.22 with an average NRS of 0.09.

300

301 **DISCUSSION**



302 Previously published research has shown that genetic resistance to DDT and the  
303 pyrethroids in common bed bugs is conferred, in part, by the presence of one or both of the  
304 V419I and L925I mutations. The goal of this project was to build upon these initial findings and  
305 determine the *kdr*-type resistance allele frequencies using QS in 12 bed bug populations  
306 collected from Israel in order to characterize the level and extent of these mutations, which lead  
307 to nerve insensitivity, so that monitoring and management strategies can be put into place.

308 Results of the DNA extraction show that the modified methods used are generally  
309 successful. For BBM1-12, the average DNA concentration was 69.8 ng/ $\mu$ L and only one sample  
310 (BBM12) was below the 10 ng/ $\mu$ L concentration prescribed for PCR. The low concentration of  
311 the BBM12 sample may partly be due to the low sample size and life stage used ( $n = 2$ , third  
312 instars). BBM12 is the only sample of the original twelve that used third instars and additionally  
313 has a sample size less than or equal to all other samples. Nevertheless, the gDNA extractions,  
314 PCR amplification and purification protocols provided sufficient and suitable products for the  
315 QS analysis.

316 Results of the QS analysis provided useful information as to the state of *kdr*-based  
317 DDT/pyrethroid resistance in Israel bed bug populations. Eleven out of the 12 samples  
318 populations lacked the V419L mutation but all 12 populations had the L925I mutation. The only  
319 populations with differing genotypes were BBM9 and BBM10. BBM9 was heterogeneous in  
320 terms of the presence of the V419L mutation (RAF = 0.39) but was homogeneous L925I  
321 mutation (RAF = 1.0). BBM10 lacked the V419L mutation (RAF = 0.0) but was heterogeneous  
322 for the L925I mutation (RAF = 0.61). Overall, only the BBM10 population did not have a RAF  
323 of 1.0 for the L925I mutation. None of the 12 sampled populations had the I936F mutation at

324 either high or intermediate levels and this mutation appears to either play no role in the genetic  
325 resistance to the pyrethroids or only a minor role.

326 A 2010 study by Zhu et al. provides relevant information for comparison to our current  
327 results. These authors investigated *kdr*-type mutations in 93 bed bug populations from across the  
328 USA and separated the populations into the following four haplotypes based on their genotypes:  
329 A (neither mutation), B (L925I but not V419L), C (both mutations), and D (V419L but not  
330 L925I). Of the 93 populations, haplotype B was the most common (44%), followed by C (39%),  
331 A (12%) and D (3%). These results are comparable with the current results from Israeli bed bug  
332 populations. Eleven out of the 12 populations tested in this study were haplotype B (BBM1-8  
333 and BBM10-12) (92%), the most common haplotype. BBM9 was haplotype C (8%), the next  
334 most common haplotype. None of the samples tested in this study were haplotype A (0%) or D  
335 (0%). The most compelling piece of information comparing the current study to the Zhu et al.  
336 (2010) study is the frequencies of the L925I versus V419L mutations. Haplotype B, while the  
337 most common haplotype in both of these studies, is overwhelming the most common in the  
338 Israeli populations (Fig. 4). Interestingly, while 36 of the 93 populations tested by Zhu et al.  
339 (2010) were haplotype C (39%), only one of the bed bug populations tested in this study showed  
340 this haplotype (8%). Most recently, Dang et al. (2014) have shown that there are high  
341 frequencies of *kdr*-type mutations associated with Australian bed bug populations, indicating the  
342 *kdr*-based pyrethroid resistance is also widespread across Australia. As found in Israel and  
343 elsewhere, haplotype B was most prevalent, haplotypes A and C were rare and haplotype D was  
344 not detected in Australia. Interestingly, two strains maintained in the laboratory, 'Moonee Ponds'  
345 and 'Darlinghurst II', appear to be losing the V419L mutation and becoming predominately  
346 haplotype B over time.

347 In 2008, Yoon et al. suggested that the L925I “may play a critical role in deltamethrin  
348 resistance”, after finding a cloned VSSC plasmid containing only this mutation, while all others  
349 contained both the L926I and V419L mutations. Seong et al. (2010) tested common bed bugs  
350 collected from Yongsan, Korea in 1993, 2007, 2008, and 2009 for *kdr*-type resistance allele  
351 frequencies using similar methods as the ones used in this study. Their findings showed no  
352 mutation for bed bugs collected in 1993, full saturation at both mutation sites in 2007, partial  
353 resistance for L925I (86%) and V419L (8%) in 2008, and 100% resistance for L925I with 0%  
354 resistance for V419L in 2009. The authors asserted that the L925I mutation appears to have been  
355 selected more intensively than the V419L mutation. The results from the Israeli bed bug  
356 populations presented here support his notion and further suggest that a fitness disadvantage may  
357 be associated with the V419L mutation.

358 Based on the trend previously shown in genetic analysis of *kdr*-based resistance in bed  
359 bugs in the USA, selective pressure appears to cause bed bugs exposed to pyrethroids to select  
360 both mutations but over time the V419L mutation is lost, leaving only the L925I mutation in  
361 heavily selected populations. If the use of pyrethroids for controlling bed bugs continues in  
362 Israel, selective pressure will likely favor the L925I haplotype. The results of this current study  
363 show that this may have already begun in Israel as 11 out of the 12 populations are homozygous  
364 for the L925I mutation with very few bed bugs maintaining the V419L mutation.

365

## 366 **Conclusion**

367 This paper aimed to elucidate the status of genetic resistance to pyrethroids in bed bug  
368 populations collected from Israel. Based on QS results, genetic testing showed that the majority  
369 of Israeli bed bugs examined in this study are resistant to pyrethroids by the *kdr* mechanism.

370 Continued use of pyrethroids on Israeli bed bugs will further select for a highly resistant  
371 populations. To effectively control these pests, alternative methods of treatments should be  
372 explored.

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

### 389 **ACKNOWLEDGMENTS**

390 This research was supported in part by a Commonwealth Honors College Research Academic  
391 Fellowship to D. Palenchar, University of Massachusetts Commonwealth Honors College,  
392 Amherst, MA 01003

393

394

395       **References Cited**

- 396       **Alderman, Z.N., K.A. Kilcullen, R. Koganemaru, M.A.E. Anderson, T.D. Anderson, and**  
397       **D.M. Millar. 2011.** Deep sequencing of pyrethroid-resistant bed bugs reveals multiple  
398       mechanisms of resistance within a single population. *PloS ONE* 6:e26228.  
399
- 400       **Bai, X., P. Mamidala, S.P. Rajarapu, S.C. Jones, and O. Mittapalli. 2011.** Transcriptomics of  
401       the bed bug (*Cimex lectularius*). *PloS ONE* 6:e16336.  
402
- 403       **Boase, C. 2004.** Bed bugs – reclaiming our cities. *Biologist*. 51(1): 9-12.  
404
- 405       **Blow, J., M. Turell, and A. Silverman. 2001.** Stercorarial shedding and transtadial transmission  
406       of hepatitis B virus by common bed bugs (Hemiptera: Cimicidae). *J. Med. Entomol.* 38(5):  
407       694-700.  
408
- 409       **Busvine, J.R. 1958.** Insecticide-resistance in bed-bugs. *Bull. Wld. Hlth. Org.* 19: 1041-1052.  
410
- 411       **Busvine J.R. 1977.** Urban pests of public health importance. *Royal Soc. Health J.* 97: 130-134.  
412
- 413       **Castèle, S., and W. Catterall. 2000.** Molecular mechanisms of neurotoxin action on voltage-  
414       gated sodium channels. *Biochemie.* 82: 883-892.  
415
- 416       **Clark, J. M, K. S. Yoon, S.H. Lee, and B. R. Pittendrigh. 2013.** Human lice: past present and  
417       future control. *Pestic. Biochem. Physiol.* 106: 162-171.

418

419 **Cwilich, R., G.G. Mer, and A.V. Meron. 1957.** Bedbugs resistant to gamma-BHC (Lindane) in  
420 Israel. *Nature*. 179: 636-637.

421

422 **Dang, K., D.G. Lilly, and S.L. Doggett. 2013.** Bed bugs and insecticide resistance ; implication  
423 for pest managers. *Pest (July/August)*: 25-27.

424

425 **Dang, K., C.S. Toi, D.G. Lilly, W. Bu, and S.L. Doggett. 2014.** Detection of knockdown  
426 resistance mutations in the common bed bug, *Cimex lectularius* (Hemiptera: Cimicidae), in  
427 Australia. *Pest Manag. Sci.* doi: 10.1002/ps.3861

428

429 **Doggett S.L., D.E. Dwyer, P.F. Penas, R.C. Russell. 2012.** Bed bug: clinical relevance and  
430 control options. *Clinical Microbio. Rev.* 25:164-192.

431

432 **Dolev E. 2007.** Allenby's military medicine: Life and death in World War I Palestine. I.B. Tauris  
433 Publ. London, pp.86-87.

434

435 **Durand, R., A. Cannet, Z. Berdjane, C. Bruel, D. Haochine, P. Delunay, and A. Izri. 2012.**  
436 Infestation by pyrethroid resistant bed bugs in the suburb of Paris, France. *Parasite* 19: 381-  
437 387.

438

- 439 **Faundez, E.I., and M. A. Carvajal. 2014.** Bed bugs are back and also arriving in the  
440 southernmost record of *Cimex lectularius* (Heteroptera: Cimicidae) in South America. J.  
441 Med. Entomol. 51:1073-1076.
- 442
- 443 **Gratz, N.G. 1958.** Insecticide resistance among insects of public health importance in Israel and  
444 neighboring countries. Tavruah 4: 26-32.
- 445
- 446 **Gratz, N.G. 1959.** A survey of bed-bug resistance to insecticides in Israel. Bull. of the World  
447 Health Org. 20: 835-840.
- 448
- 449 **Kaufmann, L. 1938.** Housing in Jewish Palestine. The Jewish Agency for Palestine, Jerusalem.  
450 pp. 25-31.
- 451
- 452 **Koganemaru, R., and D. Miller. 2013.** The bed bug problem: past, present, and future control  
453 methods. Pestic. Biochem. and Physiol. 106: 177-189.
- 454
- 455 **Koganemaru, R., D. Miller, and Z.N. Adelman. 2013.** Robust cuticular penetration resistance  
456 in the common bed bug (*Cimex lectularius* L.) correlates with increase steady-state transcript  
457 levels of CPR-type cuticular protein genes. Pestic. Biochem. and Physiol. 106: 190-197.
- 458
- 459 **Korch, C., and H. Drabkin. 1999.** Improved DNA sequencing accuracy and detection of  
460 heterozygous alleles using manganese citrate and different fluorescent dye  
461 terminators. Genome Research 9: 588-595.



462

463 **Levinson, Z.H. 1953.** The control of bedbugs (*Cimex lectularius* L.) with DDT and GBH in  
464 Israel. *Rivista Parassitologica*. 14: 233-234.

465

466 **Mamidala, P., S.C. Joned. And O. Mittapalli. 2011.** Metabolic resistance in bed bugs. *Insects*  
467 2: 36-48.

468

469 **Masetti, M., and F. Bruschi. 2007.** Bedbug infestations recorded in central Italy. *Parasitology*  
470 Int. 56: 81-83.

471

472 **Moore, D., and D. Miller. 2006.** Laboratory evaluations of insecticide product efficacy for  
473 control of *Cimex lectularius*. *J. Econ. Entomol.* 99: 2080-2086.

474

475 **Morin, S., M. Williamson, S. Goodson, J. K. Brown, B. E. Tabashnik, and T. J. Dennehy.**  
476 **2002.** Mutations in the *Bemisia tabaci para* sodium channel gene associated with resistance  
477 to a pyrethroid plus organophosphate mixture. *Insect Biochem. Mol. Biol.* 32: 1781-1791.

478

479 **Mumcuoglu, K. 2008.** A case of imported bed bug (*Cimex lectularius*) infestation in Israel.  
480 *IMAJ*. 10: 388-389.

481

482 **Mumcuoglu, K., U. Shalom. 2010.** Questionnaire survey of the common bed bug (*Cimex*  
483 *lectularius*) infestations in Israel. *J. Med. Entomol.* 40: 1-10.

484

- 485 **Reinhardt, K., and M. Siva-Jothy. 2007.** Biology of the bed bugs (Cimicidae). *Annu. Rev.*  
486 *Entomol.* 52: 351-74.  
487
- 488 **Romero, A., M. Potter, and K. Haynes. 2007.** Insecticide resistance in the bed bug: A factor in  
489 the pest's sudden resurgence? *J. Med. Entomol.* 44: 175-178.  
490
- 491 **Romero, A., M.F. Potter, and K.F. Hayes. 2009.** Evaluations of piperonyl butoxide as a  
492 deltamethrin synergist for pyrethroid-resistant bed bugs. *J. Econ. Entomol.* 102: 2310-2315.  
493
- 494 **Salazar, R., R. Castillo-Neyra, A.W. Tustin, K. Borrini-Mayorí, C. Náquira, and M.Z.**  
495 **Levy. 2014.** Bed bugs (*Cimex lectularius*) as vectors of *Trypanosoma cruzi*. *Am. J. Trop.*  
496 *Med. Hyg.* 14-0483. Published online November 17, 2014; doi:10.4269/ajtmh.14-0483.  
497
- 498 **Seong, K., D. Lee, K. Yoon, D. Kwon, H. Kim, T. Klein, J.M. Clark, and S.H. Lee. 2010.**  
499 Establishment of quantitative sequencing and filter contact vial bioassay for monitoring  
500 pyrethroid resistance in the common bed bug, *Cimex lectularius*. *J. Med. Entomol.* 47: 592-  
501 599.  
502
- 503 **Tawatsin, A., U. Thavara, and J. Chomposri. 2011.** Insecticide resistance in bed bugs in  
504 Thailand and laboratory evaluation of insecticides for the control of *Cimex hemipterus* and  
505 *Cimex lectularius* (Hemiptera: Cimicidae). *J. Med. Entomol.* 48: 1023-1030.  
506

- 507 **Tawatsin, A., K. Lorlerthum, A. Phumee, U. Thavara, J. Boon-Long, R. Boonserm, and P.**  
508 **Siriyasatien. 2013.** Discrimination between tropical bed bug *Cimex hemipterus* and common  
509 bed bug *Cimex lectularius* (Hemiptera: Cimicidae) by PCR-RFLP. Thai J. Vet. Med. 43:  
510 421-427.
- 511
- 512 **Thomas, I., G. Kihiczak, and R. Schwartz. 2004.** Bed bug bites: A review. Int. J. Dermatol.  
513 43: 430-433.
- 514
- 515 **Usinger, R.L. 1966.** Monograph of Cimicidae (Hemiptera, Heteroptera). Thomas Say  
516 Foundation, University of Maryland, College Park, MD. pp. 585.
- 517
- 518 **Wang, C., W. Tsai, R. Cooper, and J. White. 2011.** Effectiveness of bed bug monitors for  
519 detecting and trapping bed bugs in apartments. J. Econ. Entomol. 104: 274-278.
- 520
- 521 **Wang, L., Y. Xu, and L. Zeng. 2013.** Resurgence of bed bugs (Hemiptera: Cimicidae) in  
522 mainland China. Florida Entomologist 96: 131-136.
- 523
- 524 **Weeks, E., M. Birkett, M. Cameron, J.A. Pickett, and J.G. Logan. 2011.** Semiochemicals of  
525 the common bed bug, *Cimex lectularius* L. (Hemiptera: Cimicidae), and their potential for  
526 use in monitoring and control. Pest Manag. Sci. 67: 10-20.
- 527

528 **Yoon, K., D. Kwon, J. Strycharz, C. Hollingsworth, S.H. Lee, and J.M. Clark. 2008.**

529 Biochemical and molecular analysis of deltamethrin resistance in the common bed bug

530 (Hemiptera: Cimicidae). J. Med. Entomol. 45: 1092-1101.

531

532 **Zhu, F., J. Wigginton, A. Romero, A. Moore, K. Ferguson, R. Palli, M.F. Potter, K.F.**

533 **Haynes, and S.R. Palli. 2010.** Widespread distribution of knockdown resistance mutations

534 in the bed bug *Cimex lectularius* (Hemiptera: Cimicidae), population in the United States.

535 Arch. Insect. Biochem. Physiol. 73: 242-257.

536

537 **Zhu, F., H. Gujar, J.R. Gordon, K.F. Haynes, M.F. Potter, and S.R. Palli. 2013.** Bed bugs

538 evolve unique adaptive strategies to resist pyrethroid insecticides. Sci. Rep. 3:1456.

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556 **Table 1. Location and habitat of the 12 bed bug populations collected from Israel**

<b>Population #</b>	<b>Location</b>	<b>Habitat</b>
1	Jerusalem	Apartment
2	Tel Aviv	Apartment
3	Kfar Sava	Industrial Building
4	Kfar Sava	House
5	Haifa	Industrial Building
6	Hadera	Apartment
7	Eilat	Hotel
8	Tel Aviv	Hotel
9	Netanya	Apartment
10	Nazareth	House
11	Rehovot	Apartment
12	Jerusalem	House

557

558

559

560

561

562

563 **Table 2. Sample sizes and life stages of the 12 tested QS samples from bed bug**  
564 **populations collected from Israel**

<b>Population</b>	<b>Sample Size</b>	<b>Life Stage Used</b>
BBM1	4	Adult
BBM2	2	Adult
BBM3	3	Fourth instar
BBM4	4	Fourth instar
BBM5	6	Adult
BBM6	10	Fourth instar
BBM7	2	Adult
BBM8	4	Adult
BBM9	2	Adult
BBM10	5	Fourth instar
BBM11	3	Fourth instar
BBM12	2	Third instar

565

566

567

568

569

570

571

572

573

574

575

576 **Table 3. PCR and QS primers used for the amplification of DNA fragments containing**  
 577 **the V419L or L929I and I936F mutations and for sequencing reactions**

Primer name	Sequence	Purpose
3'PCRVL	5'-CTGATGGAGATTTTGCCACTGATG-3'	VL sense PCR Primer
5'PCRVL	5'-GTCCGTGGCACATGTTGTTCTTCA-3'	VL antisense PCR Primer
3'PCRLI	5'-GGAGTTCGCCATCAGGGAATCTAT-3'	LI sense PCR Primer
5'PCRLI	5'-GGTCTATCAGTTTTGAGGTCATTCAG-3'	LI antisense PCR Primer
3'QSVL	5'-CCTCTTCAGCTTCTTCTTCTT-3'	VL sequencing primer
5'QSLI	5'-GTGTTTAAGCTGGCTAAGTCATGGCC-3'	LI sequencing primer

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595 **Table 4. Nucleotide Signal Ratios (NSR) and Resistant Allele Frequencies (RAF) for bed**  
 596 **bug samples.**

Population	V419L				L925I				I936F		
	Nucleotide Signals		NSR	RAF (SD <sup>1</sup> )	Nucleotide Signals		NSR	RAF (SD <sup>1</sup> )	Nucleotide Signals		NSR
	<i>Sus.</i>	<i>Res.</i>			<i>Sus.</i>	<i>Res.</i>			<i>Sus.</i>	<i>Res.</i>	
BBM1	599	0	0.0	0.0	0	548	1.0	1.0	1049	93	0.08
BBM2	743	0	0.0	0.0	0	552	1.0	1.0	989	155	0.14
BBM3	683	0	0.0	0.0	0	582	1.0	1.0	1064	109	0.09
BBM4	516	0	0.0	0.0	0	513	1.0	1.0	979	271	0.22
BBM5	664	0	0.0	0.0	0	549	1.0	1.0	1039	81	0.07
BBM6	678	0	0.0	0.0	0	574	1.0	1.0	1082	156	0.13
BBM7	577	0	0.0	0.0	0	564	1.0	1.0	1042	106	0.09
BBM8	667	0	0.0	0.0	0	577	1.0	1.0	1046	62	0.06
BBM9	402	226	0.36	0.399 (0.032)	0	549	1.0	1.0	1093	95	0.08
BBM10	811	0	0.0	0.0	340	354	0.51	0.613 (0.002)	974	222	0.19
BBM11	757	0	0.0	0.0	0	561	1.0	1.0	1057	114	0.10
BBM12	749	0	0.0	0.0	0	555	1.0	1.0	1044	121	0.10

597 <sup>1</sup>SD = Standard Deviation.  
 598

599

600

601

602

603

604

605

606

607

608



609 **Figure Captions**

610

611 **Fig. 1.** Standard curves for V419L and L925I mutations. Resistant nucleotide signals from QS  
612 were plotted against corresponding resistant allele frequencies at the V419L (A) and L925I (B)  
613 mutations sites. Equations of the lines are listed above each graph. Black linear regression lines  
614 are shown with 95% confidence bands in red. Nucleotide signal ratios were calculated as  
615 follows: resistant nucleotide signal / [resistant nucleotide signal + susceptible nucleotide signal].

616 **Fig. 2.** Agarose gel (0.9%) electrophoresis of BBM V419L (A) and L925I purified PCR  
617 products. Lane numbers correspond to BBM test samples (i.e., 1, 2, 3 for BBM1, BBM2, BBM3  
618 etc.), a 100 basepair (bp) ladder (L, 100 – 1,200 bp, select marker sizes are indicated on left),  
619 positive control (+, BBS5 from prior experimentation), and a negative control (-, ddH<sub>2</sub>O). An  
620 asterisk (\*) indicates the expected size of the respective PCR product and corresponds to the  
621 experimental bands indicating successful PCR of the target DNA fragment. PCR products were  
622 visualized under ultraviolet light using ethidium bromide staining.

623 **Fig. 3.** Sequencing chromatograms showing differences between susceptible, mixed, and  
624 resistant nucleotide signals. On the left hand side, the VSSC amino acid substitution that results  
625 in a *kdr* mutation is indicated, and the corresponding base pair change is bolded and underlined.  
626 These same base pairs are indicated by an arrow in the chromatogram sequence, and its identity  
627 is boxed on the chromatogram base pair readout. “N” indicates that there is no sequence  
628 consensus, i.e. the population is mixed and contains both resistant and susceptible alleles.

629 **Fig. 4.** Geographic distribution of *kdr*-type mutations in common bed bug populations collected  
630 from Israel. Pie charts show haplotype frequencies for the twelve bed bug populations tested.

631 Haplotypes: A (neither mutation, black), B (L925I only, white), C (both mutations, grey).

632 Haplotype D (V419L only) is not represented in any population and is omitted.

633

634

635

636

637

638

639

640

641

642

643



644

645


646

647

648 Fig 1.



670 Fig 2.



675

676

677

678

679

680

681

682


683

684

685

686

687 Fig 3.



688

689

690

691

692

693

694

695

696

697

698


699

700

701

702

703 Fig 4.



**Table 3. PCR and QS primers used for the amplification of DNA fragments containing the V419L or L929I and I936F mutations and for sequencing reactions**

<b>Primer name</b>	<b>Sequence</b>	<b>Purpose</b>
3'PCRVL	5'-CTGATGGAGATTTTGCCACTGATG-3'	VL sense PCR Primer
5'PCRVL	5'-GTCCGTGGCACATGTTGTTCTTCA-3'	VL antisense PCR Primer
3'PCRLI	5'-GGAGTTCGCCATCAGGGAATCTAT-3'	LI sense PCR Primer
5'PCRLI	5'-GGTCTATCAGTTTTGAGGTCATTCAG-3'	LI antisense PCR Primer
3'QSVL	5'-CCTCTTCAGCTTCTTCTTCTT-3'	VL sequencing primer
5'QSLI	5'-GTGTTTAAGCTGGCTAAGTCATGGCC-3'	LI sequencing primer

**Table 4. Nucleotide Signal Ratios (NSR) and Resistant Allele Frequencies (RAF) for bed bug samples.**

Population	V419L				L925I				I936F		
	Nucleotide Signals		NSR	RAF (SD <sup>1</sup> )	Nucleotide Signals		NSR	RAF (SD <sup>1</sup> )	Nucleotide Signals		NSR
	<i>Sus.</i>	<i>Res.</i>			<i>Sus.</i>	<i>Res.</i>			<i>Sus.</i>	<i>Res.</i>	
BBM1	599	0	0.0	0.0	0	548	1.0	1.0	1049	93	0.08
BBM2	743	0	0.0	0.0	0	552	1.0	1.0	989	155	0.14
BBM3	683	0	0.0	0.0	0	582	1.0	1.0	1064	109	0.09
BBM4	516	0	0.0	0.0	0	513	1.0	1.0	979	271	0.22
BBM5	664	0	0.0	0.0	0	549	1.0	1.0	1039	81	0.07
BBM6	678	0	0.0	0.0	0	574	1.0	1.0	1082	156	0.13
BBM7	577	0	0.0	0.0	0	564	1.0	1.0	1042	106	0.09
BBM8	667	0	0.0	0.0	0	577	1.0	1.0	1046	62	0.06
BBM9	402	226	0.36	0.399 (0.032)	0	549	1.0	1.0	1093	95	0.08
BBM10	811	0	0.0	0.0	340	354	0.51	0.613 (0.002)	974	222	0.19
BBM11	757	0	0.0	0.0	0	561	1.0	1.0	1057	114	0.10
BBM12	749	0	0.0	0.0	0	555	1.0	1.0	1044	121	0.10

<sup>1</sup>SD = Standard Deviation.